EDIT Description — Editas Medicine Inc

Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. Co. has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats (CRISPR) technology and it continues to expand its capabilities. Co. is developing both in vivo CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and engineered cell medicines, in which cells are edited with Co.'s technology and then administered to the patient.

Company Name: 
Editas Medicine Inc
Number of ETFs Holding EDIT: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   EDIT Weight   EDIT Amount 
 VTI   0.01%   $115,292,392         
 VB   0.07%   $101,523,479         
 IWM   0.14%   $93,321,803         
 XBI   1.04%   $75,580,141         
 VBK   0.17%   $64,178,991         
 VXF   0.05%   $58,547,261         
 IWO   0.27%   $33,004,029         
 IBB   0.29%   $32,622,881         
 VHT   0.07%   $12,719,900         
 IDNA   2.52%   $9,398,577         
List of all 37 ETFs holding EDIT »
Quotes delayed 20 minutes

Buy (2.79 out of 4)
10th percentile
(ranked lower than approx. 90% of all stocks covered)

Analysts Forecast:
EDIT Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding EDIT | Editas Medicine Inc | ETF Channel |

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.